Work

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Year: 2020

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2020-134983

Authors: Elizabeth Budde, Ajay K. Gopal, Ian W. Flinn, Loretta J. Nastoupil, Michael S. Gordon, Ching-Fai Pang, Bruce Keyt, Steve Carroll, Maya Leabman, Genevive Hernandez, Iris Sison, Daniel Chen, Wayne Godfrey, Philippe Armand

Institutions: City Of Hope National Medical Center, Seattle Cancer Care Alliance, Sarah Cannon, Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Pinnacle Oncology Hematology, IGM Biosciences (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097839833

FWCI: 0.644

Cites:

Cited by: 10

Related to: 10